ANURAS stock
ANURAS is in a mixed news setup around Specialty Chemicals; 3 recent stories are active but the saved quote move at +0.00% keeps the read balanced.
ANURAS has built a mixed coverage cluster in the last 21 days. The strongest recurring theme is Specialty Chemicals, while the current weighted impact score is +11 from 1 bullish, 2 bearish, and 0 neutral stories across 2 sources.
ANURAS is last saved at ₹1,145 with a day move of +0.00%. That quote should be read with the article tape: a positive headline only matters if price, volume, and follow-through confirm it; a negative headline matters more when it keeps repeating across multiple publishers.
This is the first public financial report for ANURAS. The company recorded a revenue of Rs 390.14 crore and a profit of Rs 54.21 crore. These numbers show the company's financial performance for the reported period. This hub keeps the permanent stock view separate from short-lived article pages, so search engines and users get one accumulated view instead of scattered programmatic summaries.
Economic Times · 12 days ago · 2 min read
Mint · 28 days ago · 2 min read
Mint · 17 Sept 2026 · 2 min read
Economic Times · 15 Jul 2026 · 2 min read
Economic Times · 12 Jun 2026 · 2 min read
How ANURAS stacks against related names in this news cluster
ANURAS has appeared across 3 recent stories from 2 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.
ANURAS coverage is currently leaning bearish, with 1 bullish, 2 bearish, and 0 neutral analyzed stories in the recent window.
Recent ANURAS coverage is clustering around Specialty Chemicals and Chemicals. Related names showing up alongside ANURAS include ABCAPITAL, BALUFORGE, BLISSGVS.
Use this page as a coverage hub for ANURAS: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.
2 recent mentions linked to ANURAS
TopicChemicals1 recent mentions linked to ANURAS
StockABCAPITALRelated news cluster with 1 links
Latest storyBullish ANURAS: Anupam Rasayan Eyes US/Europe Pharma GrowthThe pharma sector continues to show resilience and growth, as evidenced by its outperformance agains